Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Osteosarcoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Myelosuppression 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Surgical Procedures, Operative 36Radiation 36Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × trilaciclib × Clear all
NCT06569459 2024-08-26

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡